{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:22:59Z","timestamp":1778883779358,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol. Sin."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12250-020-00306-2","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T11:05:31Z","timestamp":1604919931000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Repurposing of Antazoline Hydrochloride as an Inhibitor of Hepatitis B Virus DNA Secretion"],"prefix":"10.1016","volume":"36","author":[{"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-8155","authenticated-orcid":false,"given":"Xinwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-2944","authenticated-orcid":false,"given":"Rongjuan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"306_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","volume":"36","author":"MR Brunetto","year":"2002","unstructured":"Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F (2002) Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36:263\u2013270","journal-title":"J Hepatol"},{"key":"306_CR2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1126\/science.1077215","volume":"299","author":"K Deres","year":"2003","unstructured":"Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H (2003) Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893\u2013896","journal-title":"Science"},{"key":"306_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"EASL clinical practice guidelines","year":"2012","unstructured":"EASL clinical practice guidelines (2012) Management of chronic hepatitis B virus infection. J Hepatol 57:167\u2013185","journal-title":"J Hepatol"},{"key":"306_CR4","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bcp.13940","volume":"85","author":"MM Farkowski","year":"2019","unstructured":"Farkowski MM, Maciag A, Kowalik I, Konka M, Szwed H, Pytkowski M (2019) Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study). Br J Clin Pharmacol 85:1552\u20131558","journal-title":"Br J Clin Pharmacol"},{"key":"306_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00103-016-2333-8","volume":"59","author":"A Hampel","year":"2016","unstructured":"Hampel A, Solbach P, Cornberg M, Schmidt RE, Behrens GM, Jablonka A (2016) Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 59:578\u2013583","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"306_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","volume":"8","author":"H Kwon","year":"2011","unstructured":"Kwon H, Lok AS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8:275\u2013284","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"306_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","volume":"41","author":"SK Ladner","year":"1997","unstructured":"Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW (1997) Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41:1715\u20131720","journal-title":"Antimicrob Agents Chemother"},{"key":"306_CR8","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jhep.2015.06.006","volume":"63","author":"P Lampertico","year":"2015","unstructured":"Lampertico P, Invernizzi F, Vigano M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M (2015) The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol 63:1118\u20131125","journal-title":"J Hepatol"},{"key":"306_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.23346","volume":"50","author":"CM Lange","year":"2009","unstructured":"Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C (2009) Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 50:2001\u20132006","journal-title":"Hepatology"},{"key":"306_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV (2009) 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136:486\u2013495","journal-title":"Gastroenterology"},{"key":"306_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F (2008) Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48:750\u2013758","journal-title":"Hepatology"},{"key":"306_CR12","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","volume":"334","author":"C Niederau","year":"1996","unstructured":"Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422\u20131427","journal-title":"N Engl J Med"},{"key":"306_CR13","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30:2212\u20132219","journal-title":"Vaccine"},{"key":"306_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","volume":"34","author":"GV Papatheodoridis","year":"2001","unstructured":"Papatheodoridis GV, Manesis E, Hadziyannis SJ (2001) The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34:306\u2013313","journal-title":"J Hepatol"},{"key":"306_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000353220","volume":"6","author":"R Pei","year":"2014","unstructured":"Pei R, Qin B, Zhang X, Zhu W, Kemper T, Ma Z, Trippler M, Schlaak J, Chen X, Lu M (2014) Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J Innate Immun 6:182\u2013191","journal-title":"J Innate Immun"},{"key":"306_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.2015.2571","volume":"313","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Martin P, Lok AS (2015) Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 313:1617\u20131618","journal-title":"JAMA"},{"key":"306_CR17","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","volume":"152","author":"JB Purdy","year":"2008","unstructured":"Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R (2008) Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 152:582\u2013584","journal-title":"J Pediatr"},{"key":"306_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1128\/JVI.01902-09","volume":"84","author":"A Schulze","year":"2010","unstructured":"Schulze A, Schieck A, Ni Y, Mier W, Urban S (2010) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 84:1989\u20132000","journal-title":"J Virol"},{"key":"306_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386:1546\u20131555","journal-title":"Lancet"},{"key":"306_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479\u2013480","author":"C Seeger","year":"2015","unstructured":"Seeger C, Mason WS (2015) Molecular biology of hepatitis B virus infection. Virology 479\u2013480:672\u2013686","journal-title":"Virology"},{"key":"306_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed ZM, Cooke GS (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081\u20131088","journal-title":"Lancet"},{"key":"306_CR22","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"S Tong","year":"2016","unstructured":"Tong S, Revill P (2016) Overview of hepatitis B viral replication and genetic variability. J Hepatol 64:S4\u2013S16","journal-title":"J Hepatol"},{"key":"306_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hep.20128","volume":"39","author":"M van Zonneveld","year":"2004","unstructured":"van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804\u2013810","journal-title":"Hepatology"},{"key":"306_CR24","doi-asserted-by":"crossref","unstructured":"Wei XF, Gan CY, Cui J, Luo YY, Cai XF, Yuan Y, Shen J, Li ZY, Zhang WL, Long QX, Hu Y, Chen J, Tang N, Guo H, Huang AL, Hu JL (2018) Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay. Antimicrob Agents Chemother 62","DOI":"10.1128\/AAC.01302-18"},{"key":"306_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1099\/vir.0.012740-0","volume":"91","author":"C Wu","year":"2010","unstructured":"Wu C, Zhang X, Tian Y, Song J, Yang D, Roggendorf M, Lu M, Chen X (2010) Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol 91:483\u2013492","journal-title":"J Gen Virol"},{"key":"306_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","volume":"147","author":"CY Wu","year":"2014","unstructured":"Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147:143\u2013151.e145","journal-title":"Gastroenterology"},{"key":"306_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12250-019-00143-y","volume":"34","author":"C Wu","year":"2019","unstructured":"Wu C, Li B, Zhang X, Zhao K, Chen Y, Yuan Y, Liu Y, Chen R, Xu D, Chen X, Lu M (2019) Complementation of wild-type and drug-resistant hepatitis B virus genomes to maintain viral replication and rescue virion production under Nucleos(t)ide analogs. Virol Sin 34:377\u2013385","journal-title":"Virol Sin"},{"key":"306_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41426-018-0189-8","volume":"7","author":"K Zhao","year":"2018","unstructured":"Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Zhao H, Lu M, Wu C, Chen X (2018) Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect 7:186","journal-title":"Emerg Microbes Infect"},{"key":"306_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jviromet.2014.06.015","volume":"207","author":"M Zhou","year":"2014","unstructured":"Zhou M, Huang Y, Cheng Z, Zhao F, Li J, Zhi X, Tian X, Sun W, Hu K (2014) Revival, characterization, and hepatitis B virus infection of cryopreserved human fetal hepatocytes. J Virol Methods 207:29\u201337","journal-title":"J Virol Methods"}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-020-00306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12250-020-00306-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12250-020-00306-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T06:37:34Z","timestamp":1641278254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12250-020-00306-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["306"],"URL":"https:\/\/doi.org\/10.1007\/s12250-020-00306-2","relation":{},"ISSN":["1674-0769","1995-820X"],"issn-type":[{"value":"1674-0769","type":"print"},{"value":"1995-820X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal and Human Rights"}}]}}